ARTICLE | Clinical News

Xyotax poliglumex paclitaxel: Phase II data

May 23, 2005 7:00 AM UTC

In a Phase II trial in 82 patients, Xyotax plus carboplatin led to a major tumor response in 80 patients (98%) patients based on CA125 levels during the induction phase of the therapy. The data showe...